Navigation Links
MannKind Corporation Reports First Quarter Financial Results
Date:5/5/2008

- Conference Call Today at 5:00 p.m. EDT -

VALENCIA, Calif., May 5 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2008.

For the first quarter of 2008, total operating expenses were $74.1 million, compared to $77.3 million for the first quarter of 2007. Research and development (R&D) expenses decreased by $5.3 million to $58.4 million for the first quarter of 2008 compared to the first quarter of 2007, primarily due to lower clinical trial costs and associated packaging costs for clinical materials, partially offset by higher stock compensation expense. General and administrative (G&A) expenses increased by $2.1 million to $15.6 million for the first quarter of 2008 compared to the first quarter of 2007 primarily due to additional patent expenses.

The net loss applicable to common stockholders for the first quarter of 2008 was $71.4 million, or $0.70 per share based on 101.4 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $73.1 million, or $1.00 per share based on 73.4 million weighted average shares outstanding for the first quarter of 2007.

Cash and cash equivalents were $269.1 million at March 31, 2008 and $368.3 million at December 31, 2007.

Conference Call

MannKind management will host a conference call to discuss these results today at 5:00 p.m. EDT. To participate in the call, please dial (800) 857-0373 or (210) 839-8507. To listen to the call via the internet, please visit http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (866) 457-6651 or (203) 369-1300.

Presenting from the Company will be:

-- Chairman and Chief Executive Officer Alfred Mann

-- President and Chief Operating Officer Hakan Edstrom

-- Corporate Vice President and Chief Financial Officer Matthew Pfeffer

-- Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.

(Tables to follow)

MannKind Corporation

Condensed Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

Three Months Ended March 31,

2008 2007

Revenue $20 $10

Operating expenses:

Research and development 58,445 63,788

General and administrative 15,640 13,550

Total operating expenses 74,085 77,338

Loss from operations (74,065) (77,328)

Other income 60 52

Interest expense on senior convertible

notes (337) (1,145)

Interest income 2,921 5,280

Loss before provision for income taxes (71,421) (73,141)

Income taxes - -

Net loss applicable to common

stockholders $(71,421) $(73,141)

Net loss per share applicable to common

stockholders - basic and diluted $(0.70) $(1.00)

Shares used to compute basic and diluted

net loss per share applicable to common

stockholders 101,409 73,388

MannKind Corporation

Condensed Balance Sheets

(Unaudited)

(in thousands)

March 31, December 31,

Assets 2008 2007

Current assets:

Cash and cash equivalents $269,079 $368,285

State research and development tax credit

exchange receivable - current - 831

Prepaid expenses and other current assets 8,004 9,596

Total current assets 277,083 378,712

Property and equipment - net 185,895 162,683

State research and development tax credit

exchange receivable - net of current portion 1,875 1,500

Other assets 549 548

Total $465,402 $543,443

Liabilities and Stockholders' Equity

Current liabilities $55,447 $67,558

Other liabilities - 24

Senior convertible notes 111,882 111,761

Stockholders' equity 298,073 364,100

Total $465,402 $543,443


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling ... (CSO) that provides biopharma companies the experience, expertise, ... and deploy outsourced sales teams. Created in concert ... addresses both the strategic and tactical needs of ... sales solutions through both personal and non-personal promotion. ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols and ... from around the world. , The new GSCG clinic is headed by ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
Breaking Biology Technology:
(Date:2/3/2016)... LIVERMORE, Calif. , Feb. 3, 2016 ... Police Department in Missouri ... of license plate reader (LPR) data from Vigilant Solutions. ... a hit-and-run case in which the victim was walking out ... a parking space next to his vehicle, striking his ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
Breaking Biology News(10 mins):